Stocks are hitting the ceiling! Since October, 10 A-share listed companies have announced being targeted, with china national medicines corporation and sh pharma being targeted on the same day by new china life insurance.
① According to incomplete statistics, since October, 10 A-share listed companies including zhejiang east crystal electronic, semiconductor manufacturing international corporation, quanjinhao, lifecome biochemistry, zhejiang jingu, primeton information technologies, inc., guangzhou goaland energy conservation tech, xuzhou handler special vehicle, china national medicines corporation, and sh pharma have announced that they have received major stock purchases from relevant parties (see attached table). ② In the secondary market, this week, xuzhou handler special vehicle and guangzhou goaland energy conservation tech have both seen their stock prices increase by more than 100% since September.
A-share dividends set a new record! List of top stocks in terms of dividend per share in the third quarter.
1. The data shows that the number and total amount of cash dividends proposed in the third quarter reports of A-share listed companies in Shanghai and Shenzhen in 2024 have both reached historical highs; 2. G-bits ranks first in the third quarter dividend list with a dividend of 2 yuan per share, leading the list of stocks with dividend per share in the third quarter (see table).
Zhangzhou Pientzehuang Pharmaceutical has acquired shares in Fujian Cosunter Pharmaceutical? The innovative drugs track sees the resurgence of players in the traditional chinese medicine industry | Speed-read announcement
fujian cosunter pharmaceutical announced that Yuanshan Fund plans to become a shareholder with a transfer payment of nearly 0.2 billion yuan, holding more than 5% of the company's shares. Yuanshan Fund partners include state-owned wholly-owned companies, zhangzhou pientzehuang pharmaceutical wholly-owned subsidiaries, among which Zhangzhou Pientzehuang Investment is the largest limited partner in terms of fund contribution proportion.
"Going global" and "innovation" are the key words that cannot be bypassed. Sun Piaoyang from Jiangsu Hengrui Pharmaceuticals, Zhu Yi from Baheal Pharm and other top pharmaceutical industry leaders jointly discuss the next decade | Industry Observation
① On November 14, 2024, the Qisi Conference opened in Chengdu, where experts in the pharmaceutical field, investors, and chairpersons of leading listed companies discussed the challenges and opportunities currently facing the china meheco group industry. ② The two key phrases "going overseas" and "innovation" ran throughout the meeting. ③ In response to the question of the future direction of innovative drugs in china, various companies provided different answers.
Innovative phar (00399.HK) will hold a board of directors meeting on November 29 to approve the mid-term performance.
Gelonghui announced on November 14 that innovative phar (00399.HK) will hold a board of directors meeting on Friday, November 29, 2024, to consider and approve (including) the consolidated interim results of the company and its subsidiaries for the six months ended September 30, 2024.
Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.
① During the earnings conference, fosun pharma stated that the company's performance improved year-on-year in Q3 due to factors such as the continuous increase in innovative drug volume. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the rapid上市 and sales of injectable type A botulinum toxin within china. ③ The privatization process of henlius and the accessibility of CAR-T products are also receiving significant attention.